{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:48:19Z","timestamp":1794278899141,"version":"4.9.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05428-w","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T01:10:29Z","timestamp":1763601029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Therapeutic Potential of Sodium Butyrate in Neurological and Psychiatric Disorders"],"prefix":"10.1007","volume":"63","author":[{"given":"Dibachehr","family":"Rahmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Chodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kakallahpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Niknam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"1","key":"5428_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/1570159X19666210609160017","volume":"20","author":"V Kumar","year":"2022","unstructured":"Kumar V et al (2022) Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective. Curr Neuropharmacol 20(1):158","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"5428_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM et al (2023) Hallmarks of neurodegenerative diseases. Cell 186(4):693\u2013714","journal-title":"Cell"},{"issue":"5","key":"5428_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"AD Gitler","year":"2017","unstructured":"Gitler AD, Dhillon P, Shorter J (2017) Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech 10(5):499\u2013502","journal-title":"Dis Model Mech"},{"key":"5428_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11010-010-0563-x","volume":"345","author":"K Jomova","year":"2010","unstructured":"Jomova K et al (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345:91\u2013104","journal-title":"Mol Cell Biochem"},{"issue":"7","key":"5428_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/cns.13116","volume":"25","author":"Y Wang","year":"2019","unstructured":"Wang Y et al (2019) Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure. CNS Neurosci Ther 25(7):816\u2013824","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"5428_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12906-022-03816-6","volume":"22","author":"M Pourhadi","year":"2022","unstructured":"Pourhadi M et al (2022) Cuscuta epithymum Murr. crude extract pre-conditioning protects C6 cells from L-glutamate-induced neurotoxicity. BMC Complementary Medicine and Therapies 22(1):335","journal-title":"BMC Complementary Medicine and Therapies"},{"issue":"20","key":"5428_CR7","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","volume":"15","author":"E Kontopoulos","year":"2006","unstructured":"Kontopoulos E, Parvin JD, Feany MB (2006) \u03b1-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15(20):3012\u20133023","journal-title":"Hum Mol Genet"},{"issue":"1","key":"5428_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-017-0807-8","volume":"14","author":"J Jaworska","year":"2017","unstructured":"Jaworska J et al (2017) The potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia. J Neuroinflammation 14(1):1\u201317","journal-title":"J Neuroinflammation"},{"issue":"8","key":"5428_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1017\/S1461145708009024","volume":"11","author":"X Wu","year":"2008","unstructured":"Wu X et al (2008) Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11(8):1123\u20131134","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"5428_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neulet.2009.10.037","volume":"467","author":"Y Wang","year":"2009","unstructured":"Wang Y et al (2009) HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci Lett 467(3):212\u2013216","journal-title":"Neurosci Lett"},{"issue":"11","key":"5428_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.tins.2009.06.002","volume":"32","author":"D-M Chuang","year":"2009","unstructured":"Chuang D-M et al (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32(11):591\u2013601","journal-title":"Trends Neurosci"},{"issue":"28","key":"5428_CR12","doi-asserted-by":"publisher","first-page":"7929","DOI":"10.1080\/10408398.2021.1920884","volume":"62","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Liu J, Ling Z (2022) Short-chain fatty acids-producing probiotics: a novel source of psychobiotics. Crit Rev Food Sci Nutr 62(28):7929\u20137959","journal-title":"Crit Rev Food Sci Nutr"},{"key":"5428_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neulet.2016.02.009","volume":"625","author":"MW Bourassa","year":"2016","unstructured":"Bourassa MW et al (2016) Butyrate, neuroepigenetics and the gut microbiome: can a high fiber diet improve brain health? Neurosci Lett 625:56\u201363","journal-title":"Neurosci Lett"},{"issue":"4","key":"5428_CR14","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41380-022-01456-3","volume":"27","author":"A McGuinness","year":"2022","unstructured":"McGuinness A et al (2022) A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry 27(4):1920\u20131935","journal-title":"Mol Psychiatry"},{"key":"5428_CR15","doi-asserted-by":"publisher","first-page":"111661","DOI":"10.1016\/j.biopha.2021.111661","volume":"139","author":"R Mirzaei","year":"2021","unstructured":"Mirzaei R et al (2021) Role of microbiota-derived short-chain fatty acids in nervous system disorders. Biomed Pharmacother 139:111661","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"5428_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1017\/S0007114519001399","volume":"122","author":"B Sun","year":"2019","unstructured":"Sun B et al (2019) Sodium butyrate protects against high-fat diet-induced oxidative stress in rat liver by promoting expression of nuclear factor E2-related factor 2. Br J Nutr 122(4):400\u2013410","journal-title":"Br J Nutr"},{"issue":"4","key":"5428_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/nu15040930","volume":"15","author":"T-T Guo","year":"2023","unstructured":"Guo T-T et al (2023) Neuroprotective effects of sodium butyrate by restoring gut microbiota and inhibiting TLR4 signaling in mice with MPTP-induced Parkinson\u2019s disease. Nutrients 15(4):930","journal-title":"Nutrients"},{"issue":"2","key":"5428_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1574-6968.2002.tb11467.x","volume":"217","author":"SE Pryde","year":"2002","unstructured":"Pryde SE et al (2002) The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 217(2):133\u2013139","journal-title":"FEMS Microbiol Lett"},{"issue":"8","key":"5428_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-019-0157-3","volume":"16","author":"B Dalile","year":"2019","unstructured":"Dalile B et al (2019) The role of short-chain fatty acids in microbiota\u2013gut\u2013brain communication. Nat Rev Gastroenterol Hepatol 16(8):461\u2013478","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"5428_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/advances\/nmz004","volume":"10","author":"C Alexander","year":"2019","unstructured":"Alexander C et al (2019) Perspective: physiologic importance of short-chain fatty acids from nondigestible carbohydrate fermentation. Adv Nutr 10(4):576\u2013589","journal-title":"Adv Nutr"},{"issue":"1","key":"5428_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JAD-190120","volume":"74","author":"W Fernando","year":"2020","unstructured":"Fernando W et al (2020) Sodium butyrate reduces brain amyloid-\u03b2 levels and improves cognitive memory performance in an Alzheimer\u2019s disease transgenic mouse model at an early disease stage. J Alzheimers Dis 74(1):91\u201399","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"5428_CR22","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1007\/s11064-021-03369-z","volume":"46","author":"AB Bayazid","year":"2021","unstructured":"Bayazid AB et al (2021) Neuroprotective effects of sodium butyrate through suppressing neuroinflammation and modulating antioxidant enzymes. Neurochem Res 46(9):2348\u20132358","journal-title":"Neurochem Res"},{"issue":"1","key":"5428_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3748\/wjg.v23.i1.60","volume":"23","author":"D Zhou","year":"2017","unstructured":"Zhou D et al (2017) Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol 23(1):60","journal-title":"World J Gastroenterol"},{"key":"5428_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7605160","author":"J Sun","year":"2020","unstructured":"Sun J et al (2020) Sodium butyrate protects N2a cells against A\u03b2 toxicity in vitro. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2020\/7605160","journal-title":"Mediators Inflamm"},{"issue":"4","key":"5428_CR25","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.14336\/AD.2021.1215","volume":"13","author":"X-h Qian","year":"2022","unstructured":"Qian X-h et al (2022) Mechanisms of short-chain fatty acids derived from gut microbiota in Alzheimer\u2019s disease. Aging Dis 13(4):1252","journal-title":"Aging Dis"},{"issue":"1","key":"5428_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14737175.2018.1400909","volume":"18","author":"L Ho","year":"2018","unstructured":"Ho L et al (2018) Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer\u2019s disease-type beta-amyloid neuropathological mechanisms. Expert Rev Neurother 18(1):83\u201390","journal-title":"Expert Rev Neurother"},{"key":"5428_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fendo.2020.00025","volume":"11","author":"YP Silva","year":"2020","unstructured":"Silva YP, Bernardi A, Frozza RL (2020) The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol 11:25","journal-title":"Front Endocrinol"},{"issue":"9\u201310","key":"5428_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1159\/000505132","volume":"105","author":"J Qiu","year":"2020","unstructured":"Qiu J et al (2020) Lipopolysaccharide-induced depression-like behaviors is ameliorated by sodium butyrate via inhibiting neuroinflammation and oxido-nitrosative stress. Pharmacology 105(9\u201310):550\u2013560","journal-title":"Pharmacology"},{"key":"5428_CR29","doi-asserted-by":"publisher","first-page":"109452","DOI":"10.1016\/j.cbi.2021.109452","volume":"341","author":"Y Jiang","year":"2021","unstructured":"Jiang Y et al (2021) Sodium butyrate ameliorates the impairment of synaptic plasticity by inhibiting the neuroinflammation in 5XFAD mice. Chem Biol Interact 341:109452","journal-title":"Chem Biol Interact"},{"key":"5428_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jns.2017.08.3235","volume":"381","author":"J Liu","year":"2017","unstructured":"Liu J et al (2017) Sodium butyrate exerts protective effect against Parkinson\u2019s disease in mice via stimulation of glucagon like peptide-1. J Neurol Sci 381:176\u2013181","journal-title":"J Neurol Sci"},{"key":"5428_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s12035-014-8914-3","volume":"52","author":"T Barichello","year":"2015","unstructured":"Barichello T et al (2015) Sodium butyrate prevents memory impairment by re-establishing BDNF and GDNF expression in experimental pneumococcal meningitis. Mol Neurobiol 52:734\u2013740","journal-title":"Mol Neurobiol"},{"key":"5428_CR32","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1007\/s12035-018-1347-7","volume":"56","author":"M Lanza","year":"2019","unstructured":"Lanza M et al (2019) Sodium butyrate exerts neuroprotective effects in spinal cord injury. Mol Neurobiol 56:3937\u20133947","journal-title":"Mol Neurobiol"},{"issue":"3","key":"5428_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/nu13030732","volume":"13","author":"SM-S Tran","year":"2021","unstructured":"Tran SM-S, Mohajeri MH (2021) The role of gut bacterial metabolites in brain development, aging and disease. Nutrients 13(3):732","journal-title":"Nutrients"},{"key":"5428_CR34","doi-asserted-by":"publisher","first-page":"1103836","DOI":"10.3389\/fmicb.2022.1103836","volume":"13","author":"V Singh","year":"2023","unstructured":"Singh V et al (2023) Butyrate producers, \u201cthe sentinel of gut\u201d: their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. Front Microbiol 13:1103836","journal-title":"Front Microbiol"},{"issue":"1","key":"5428_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/biom15010085","volume":"15","author":"W Chen","year":"2025","unstructured":"Chen W et al (2025) Butyrate supplementation improves intestinal health and growth performance in livestock: a review. Biomolecules 15(1):85","journal-title":"Biomolecules"},{"key":"5428_CR36","doi-asserted-by":"publisher","first-page":"1527755","DOI":"10.3389\/fmicb.2025.1527755","volume":"16","author":"S Kumar","year":"2025","unstructured":"Kumar S et al (2025) Unveiling roles of beneficial gut bacteria and optimal diets for health. Front Microbiol 16:1527755","journal-title":"Front Microbiol"},{"key":"5428_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33997","author":"C Zhou","year":"2024","unstructured":"Zhou C et al (2024) Role of histone deacetylase inhibitors in non-neoplastic diseases. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33997","journal-title":"Heliyon"},{"key":"5428_CR38","doi-asserted-by":"publisher","first-page":"112743","DOI":"10.1016\/j.fct.2021.112743","volume":"159","author":"JG Kim","year":"2022","unstructured":"Kim JG, Bayazid AB, Azam S, Jeong SA, Kim DH, Park CW, Lim BO (2022) Sodium butyrate ameliorates neurotoxicity and exerts anti-inflammatory effects in high fat diet-fed mice. Food Chem Toxicol 159:112743. https:\/\/doi.org\/10.1016\/j.fct.2021.112743","journal-title":"Food Chem Toxicol"},{"key":"5428_CR39","doi-asserted-by":"publisher","first-page":"113528","DOI":"10.1016\/j.biopha.2022.113528","volume":"153","author":"C Cristiano","year":"2022","unstructured":"Cristiano C et al (2022) Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction. Biomed Pharmacother 153:113528","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5428_CR40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s11033-024-09641-z","volume":"51","author":"G Tanhai","year":"2024","unstructured":"Tanhai G et al (2024) Ameliorative properties of quercetin in the treatment of traumatic brain injury: a mechanistic review based on underlying mechanisms. Mol Biol Rep 51(1):695","journal-title":"Mol Biol Rep"},{"key":"5428_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.brainres.2016.03.031","volume":"1642","author":"H Li","year":"2016","unstructured":"Li H et al (2016) Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in traumatic brain injury mice. Brain Res 1642:70\u201378","journal-title":"Brain Res"},{"issue":"4","key":"5428_CR42","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jid.2016.11.014","volume":"137","author":"A Schwarz","year":"2017","unstructured":"Schwarz A, Bruhs A, Schwarz T (2017) The short-chain fatty acid sodium butyrate functions as a regulator of the skin immune system. J Invest Dermatol 137(4):855\u2013864","journal-title":"J Invest Dermatol"},{"key":"5428_CR43","doi-asserted-by":"publisher","first-page":"110061","DOI":"10.1016\/j.intimp.2023.110061","volume":"118","author":"MA Abd Elmaaboud","year":"2023","unstructured":"Abd Elmaaboud MA et al (2023) The immunomodulatory effects of ethosuximide and sodium butyrate on experimentally induced fibromyalgia: the interaction between IL-4, synaptophysin, and TGF-\u03b21\/NF-\u03baB signaling. Int Immunopharmacol 118:110061","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"5428_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/nu8120728","volume":"8","author":"T Zhang","year":"2016","unstructured":"Zhang T et al (2016) Sodium butyrate reduces colitogenic immunoglobulin A-coated bacteria and modifies the composition of microbiota in IL-10 deficient mice. Nutrients 8(12):728","journal-title":"Nutrients"},{"issue":"11","key":"5428_CR45","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/hmg\/ddh131","volume":"13","author":"M Minamiyama","year":"2004","unstructured":"Minamiyama M (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13(11):1183\u20131192","journal-title":"Hum Mol Genet"},{"issue":"2","key":"5428_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.nbd.2010.10.019","volume":"41","author":"A-H Chou","year":"2011","unstructured":"Chou A-H et al (2011) HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis 41(2):481\u2013488","journal-title":"Neurobiol Dis"},{"key":"5428_CR47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.neuropharm.2015.11.003","volume":"102","author":"N Kratsman","year":"2016","unstructured":"Kratsman N, Getselter D, Elliott E (2016) Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory\/excitatory genes in the frontal cortex of an autism model. Neuropharmacology 102:136\u2013145","journal-title":"Neuropharmacology"},{"key":"5428_CR48","doi-asserted-by":"publisher","unstructured":"Wang C et al (2022) Sodium butyrate ameliorates the cognitive impairment of Alzheimer\u2019s disease by regulating the metabolism of astrocytes. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-021-06025-0","DOI":"10.1007\/s00213-021-06025-0"},{"issue":"1","key":"5428_CR49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3233\/JAD-2011-110080","volume":"26","author":"N Govindarajan","year":"2011","unstructured":"Govindarajan N et al (2011) Sodium butyrate improves memory function in an Alzheimer\u2019s disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 26(1):187\u2013197","journal-title":"J Alzheimers Dis"},{"key":"5428_CR50","doi-asserted-by":"publisher","first-page":"111376","DOI":"10.1016\/j.exger.2021.111376","volume":"150","author":"Y Hou","year":"2021","unstructured":"Hou Y et al (2021) Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson\u2019s disease. Exp Gerontol 150:111376","journal-title":"Exp Gerontol"},{"key":"5428_CR51","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.neuroscience.2013.04.037","volume":"246","author":"RS Laurent","year":"2013","unstructured":"Laurent RS, O\u2019Brien LM, Ahmad S (2013) Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson\u2019s disease. Neuroscience 246:382\u2013390","journal-title":"Neuroscience"},{"key":"5428_CR52","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbr.2015.05.052","volume":"291","author":"S Sharma","year":"2015","unstructured":"Sharma S, Taliyan R, Singh S (2015) Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav Brain Res 291:306\u2013314","journal-title":"Behav Brain Res"},{"key":"5428_CR53","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12640-020-00238-5","volume":"38","author":"B Getachew","year":"2020","unstructured":"Getachew B et al (2020) Butyrate protects against salsolinol-induced toxicity in SH-SY5Y cells: implication for Parkinson\u2019s disease. Neurotox Res 38:596\u2013602","journal-title":"Neurotox Res"},{"issue":"28","key":"5428_CR54","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","volume":"23","author":"RJ Ferrante","year":"2003","unstructured":"Ferrante RJ et al (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice. J Neurosci 23(28):9418\u20139427","journal-title":"J Neurosci"},{"issue":"6857","key":"5428_CR55","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/35099568","volume":"413","author":"JS Steffan","year":"2001","unstructured":"Steffan JS et al (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857):739\u2013743","journal-title":"Nature"},{"issue":"43","key":"5428_CR56","doi-asserted-by":"publisher","first-page":"11174","DOI":"10.1523\/JNEUROSCI.3004-06.2006","volume":"26","author":"JM Oliveira","year":"2006","unstructured":"Oliveira JM et al (2006) Mitochondrial-dependent Ca2+ handling in Huntington\u2019s disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci 26(43):11174\u201311186","journal-title":"J Neurosci"},{"issue":"10","key":"5428_CR57","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1523\/JNEUROSCI.2006-14.2016","volume":"37","author":"L Naia","year":"2017","unstructured":"Naia L et al (2017) Histone deacetylase inhibitors protect against pyruvate dehydrogenase dysfunction in Huntington\u2019s disease. J Neurosci 37(10):2776\u20132794","journal-title":"J Neurosci"},{"issue":"2","key":"5428_CR58","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clinthera.2016.12.014","volume":"39","author":"Y-g Zhang","year":"2017","unstructured":"Zhang Y-g et al (2017) Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther 39(2):322\u2013336","journal-title":"Clin Ther"},{"issue":"12","key":"5428_CR59","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3390\/metabo12121253","volume":"12","author":"D Ogbu","year":"2022","unstructured":"Ogbu D et al (2022) Target metabolites to slow down progression of amyotrophic lateral sclerosis in mice. Metabolites 12(12):1253","journal-title":"Metabolites"},{"key":"5428_CR60","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neuropharm.2014.02.017","volume":"81","author":"A Han","year":"2014","unstructured":"Han A et al (2014) Possible additional antidepressant-like mechanism of sodium butyrate: targeting the hippocampus. Neuropharmacology 81:292\u2013302","journal-title":"Neuropharmacology"},{"issue":"4","key":"5428_CR61","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2174\/1567202612666150728121121","volume":"12","author":"S Valvassori","year":"2015","unstructured":"Valvassori S et al (2015) Sodium butyrate, a histone deacetylase inhibitor, reverses behavioral and mitochondrial alterations in animal models of depression induced by early-or late-life stress. Curr Neurovasc Res 12(4):312\u2013320","journal-title":"Curr Neurovasc Res"},{"key":"5428_CR62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2017.12.004","volume":"1680","author":"Y Yamawaki","year":"2018","unstructured":"Yamawaki Y et al (2018) Sodium butyrate abolishes lipopolysaccharide-induced depression-like behaviors and hippocampal microglial activation in mice. Brain Res 1680:13\u201338","journal-title":"Brain Res"},{"key":"5428_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neulet.2016.03.003","volume":"618","author":"J Sun","year":"2016","unstructured":"Sun J et al (2016) Antidepressant-like effects of sodium butyrate and its possible mechanisms of action in mice exposed to chronic unpredictable mild stress. Neurosci Lett 618:159\u2013166","journal-title":"Neurosci Lett"},{"issue":"8","key":"5428_CR64","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/FBP.0b013e32834d0f1b","volume":"22","author":"M Moretti","year":"2011","unstructured":"Moretti M et al (2011) Behavioral and neurochemical effects of sodium butyrate in an animal model of mania. Behav Pharmacol 22(8):766\u2013772","journal-title":"Behav Pharmacol"},{"issue":"4","key":"5428_CR65","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.neuint.2013.02.001","volume":"62","author":"AV Steckert","year":"2013","unstructured":"Steckert AV et al (2013) Effects of sodium butyrate on oxidative stress and behavioral changes induced by administration of D-AMPH. Neurochem Int 62(4):425\u2013432","journal-title":"Neurochem Int"},{"issue":"7","key":"5428_CR66","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/FBP.0b013e32836546fc","volume":"24","author":"WR Resende","year":"2013","unstructured":"Resende WR et al (2013) Effects of sodium butyrate in animal models of mania and depression: implications as a new mood stabilizer. Behav Pharmacol 24(7):569\u2013579","journal-title":"Behav Pharmacol"},{"issue":"6","key":"5428_CR67","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/15622975.2011.585663","volume":"13","author":"Y Yamawaki","year":"2012","unstructured":"Yamawaki Y et al (2012) Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J Biol Psychiatry 13(6):458\u2013467","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"5428_CR68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.biopsych.2006.06.036","volume":"62","author":"FA Schroeder","year":"2007","unstructured":"Schroeder FA et al (2007) Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 62(1):55\u201364","journal-title":"Biol Psychiatry"},{"key":"5428_CR69","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jpsychires.2014.11.003","volume":"61","author":"RB Varela","year":"2015","unstructured":"Varela RB et al (2015) Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats. J Psychiatr Res 61:114\u2013121","journal-title":"J Psychiatr Res"},{"key":"5428_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.psychres.2015.11.017","volume":"235","author":"SS Valvassori","year":"2016","unstructured":"Valvassori SS et al (2016) Sodium butyrate has an antimanic effect and protects the brain against oxidative stress in an animal model of mania induced by ouabain. Psychiatr Res 235:154\u2013159","journal-title":"Psychiatr Res"},{"key":"5428_CR71","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/395895","author":"J Sun","year":"2015","unstructured":"Sun J et al (2015) Neuroprotective effect of sodium butyrate against cerebral ischemia\/reperfusion injury in mice. Biomed Res Int. https:\/\/doi.org\/10.1155\/2015\/395895","journal-title":"Biomed Res Int"},{"issue":"3","key":"5428_CR72","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1124\/jpet.107.120188","volume":"321","author":"HJ Kim","year":"2007","unstructured":"Kim HJ et al (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321(3):892\u2013901","journal-title":"J Pharmacol Exp Ther"},{"key":"5428_CR73","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1007\/s12035-016-0049-2","volume":"54","author":"M Ziemka-Nalecz","year":"2017","unstructured":"Ziemka-Nalecz M et al (2017) Sodium butyrate, a histone deacetylase inhibitor, exhibits neuroprotective\/neurogenic effects in a rat model of neonatal hypoxia-ischemia. Mol Neurobiol 54:5300\u20135318","journal-title":"Mol Neurobiol"},{"key":"5428_CR74","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1007\/s12035-016-0149-z","volume":"54","author":"R Patnala","year":"2017","unstructured":"Patnala R et al (2017) HDAC inhibitor sodium butyrate-mediated epigenetic regulation enhances neuroprotective function of microglia during ischemic stroke. Mol Neurobiol 54:6391\u20136411","journal-title":"Mol Neurobiol"},{"key":"5428_CR75","doi-asserted-by":"publisher","first-page":"117864692097840","DOI":"10.1177\/1178646920978404","volume":"13","author":"ML Garcez","year":"2020","unstructured":"Garcez ML et al (2020) Sodium butyrate and indole-3-propionic acid prevent the increase of cytokines and kynurenine levels in LPS-induced human primary astrocytes. Int J Tryptophan Res 13:1178646920978404","journal-title":"Int J Tryptophan Res"},{"issue":"1","key":"5428_CR76","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0165-3806(87)90096-4","volume":"31","author":"JC Byrd","year":"1987","unstructured":"Byrd JC, Alho H (1987) Differentiation of PC12 pheochromocytoma cells by sodium butyrate. Dev Brain Res 31(1):151\u2013155","journal-title":"Dev Brain Res"},{"issue":"24","key":"5428_CR77","doi-asserted-by":"publisher","first-page":"11699","DOI":"10.1016\/S0021-9258(18)60867-1","volume":"262","author":"J Byrd","year":"1987","unstructured":"Byrd J, Lichti U (1987) Two types of transglutaminase in the PC12 pheochromocytoma cell line. Stimulation by sodium butyrate. J Biol Chem 262(24):11699\u201311705","journal-title":"J Biol Chem"},{"issue":"5","key":"5428_CR78","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s43440-022-00384-x","volume":"74","author":"K Ziabska","year":"2022","unstructured":"Ziabska K et al (2022) The impact of the histone deacetylase inhibitor sodium butyrate on microglial polarization after oxygen and glucose deprivation. Pharmacol Rep 74(5):909\u2013919","journal-title":"Pharmacol Rep"},{"key":"5428_CR79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neulet.2018.01.006","volume":"668","author":"S Jang","year":"2018","unstructured":"Jang S, Jeong H-S (2018) Histone deacetylase inhibition-mediated neuronal differentiation via the Wnt signaling pathway in human adipose tissue-derived mesenchymal stem cells. Neurosci Lett 668:24\u201330","journal-title":"Neurosci Lett"},{"key":"5428_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2019.03.049","volume":"704","author":"H Liu","year":"2019","unstructured":"Liu H et al (2019) Differentiation of human glioblastoma U87 cells into cholinergic neuron. Neurosci Lett 704:1\u20137","journal-title":"Neurosci Lett"},{"issue":"3","key":"5428_CR81","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41419-018-0396-1","volume":"9","author":"M Uittenbogaard","year":"2018","unstructured":"Uittenbogaard M, Brantner CA, Chiaramello A (2018) Epigenetic modifiers promote mitochondrial biogenesis and oxidative metabolism leading to enhanced differentiation of neuroprogenitor cells. Cell Death Dis 9(3):360","journal-title":"Cell Death Dis"},{"key":"5428_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-017-0097-1","volume":"6","author":"P Tabeshmehr","year":"2017","unstructured":"Tabeshmehr P et al (2017) Nicorandil potentiates sodium butyrate induced preconditioning of neurons and enhances their survival upon subsequent treatment with H 2 O 2. Transl Neurodegener 6:1\u20139","journal-title":"Transl Neurodegener"},{"key":"5428_CR83","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12035-013-8441-7","volume":"48","author":"C N\u00f6r","year":"2013","unstructured":"N\u00f6r C et al (2013) The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells. Mol Neurobiol 48:533\u2013543","journal-title":"Mol Neurobiol"},{"key":"5428_CR84","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1007\/s12035-018-0874-6","volume":"55","author":"BK Souza","year":"2018","unstructured":"Souza BK et al (2018) Targeting histone deacetylase activity to arrest cell growth and promote neural differentiation in Ewing sarcoma. Mol Neurobiol 55:7242\u20137258","journal-title":"Mol Neurobiol"},{"key":"5428_CR85","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1007\/s12640-021-00418-x","volume":"39","author":"B Getachew","year":"2021","unstructured":"Getachew B et al (2021) Sodium butyrate protects against ethanol-induced toxicity in SH-SY5Y cell line. Neurotox Res 39:2186\u20132193","journal-title":"Neurotox Res"},{"issue":"1","key":"5428_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12640-023-00682-z","volume":"42","author":"Y Tizabi","year":"2024","unstructured":"Tizabi Y, Getachew B, Aschner M (2024) Butyrate protects and synergizes with nicotine against iron-and manganese-induced toxicities in cell culture. Neurotox Res 42(1):3","journal-title":"Neurotox Res"},{"issue":"1","key":"5428_CR87","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11033-024-09242-w","volume":"51","author":"K Asghari","year":"2024","unstructured":"Asghari K et al (2024) Cellular junction dynamics and Alzheimer\u2019s disease: a comprehensive review. Mol Biol Rep 51(1):273","journal-title":"Mol Biol Rep"},{"key":"5428_CR88","doi-asserted-by":"publisher","DOI":"10.5812\/ijpr-133668","author":"F Mohebichamkhorami","year":"2022","unstructured":"Mohebichamkhorami F et al (2022) Brain homogenate of a rat model of Alzheimer\u2019s disease modifies the secretome of 3D cultured periodontal ligament stem cells: a potential neuroregenerative therapy. Iranian Journal of Pharmaceutical Research: IJPR. https:\/\/doi.org\/10.5812\/ijpr-133668","journal-title":"Iranian Journal of Pharmaceutical Research: IJPR"},{"issue":"1","key":"5428_CR89","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12993-024-00257-8","volume":"20","author":"M Aliashrafi","year":"2024","unstructured":"Aliashrafi M et al (2024) CutibacteriumAcnes induces Alzheimer\u2019s disease-like pathology in brains of wistar rats through structural changes associated with microtubules. Behav Brain Funct 20(1):30","journal-title":"Behav Brain Funct"},{"issue":"24","key":"5428_CR90","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Karaman R (2020) Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules 25(24):5789","journal-title":"Molecules"},{"issue":"1","key":"5428_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W et al (2017) Parkinson disease. Nat Rev Dis Primers 3(1):1\u201321","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"5428_CR92","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/mds.28052","volume":"35","author":"MS Cirstea","year":"2020","unstructured":"Cirstea MS et al (2020) Microbiota composition and metabolism are associated with gut function in Parkinson\u2019s disease. Mov Disord 35(7):1208\u20131217","journal-title":"Mov Disord"},{"key":"5428_CR93","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10565-020-09518-4","volume":"36","author":"X Ma","year":"2020","unstructured":"Ma X et al (2020) Sodium butyrate modulates gut microbiota and immune response in colorectal cancer liver metastatic mice. Cell Biol Toxicol 36:509\u2013515","journal-title":"Cell Biol Toxicol"},{"issue":"5","key":"5428_CR94","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jnutbio.2011.01.007","volume":"23","author":"EL Vieira","year":"2012","unstructured":"Vieira EL et al (2012) Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem 23(5):430\u2013436","journal-title":"J Nutr Biochem"},{"key":"5428_CR95","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","volume":"11","author":"JS Paulsen","year":"2011","unstructured":"Paulsen JS (2011) Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 11:474\u2013483","journal-title":"Curr Neurol Neurosci Rep"},{"key":"5428_CR96","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10897-014-9755-y","volume":"24","author":"S Crozier","year":"2015","unstructured":"Crozier S, Robertson N, Dale M (2015) The psychological impact of predictive genetic testing for Huntington\u2032 s disease: a systematic review of the literature. J Genet Couns 24:29\u201339","journal-title":"J Genet Couns"},{"key":"5428_CR97","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11940-013-0219-8","volume":"15","author":"A Videnovic","year":"2013","unstructured":"Videnovic A (2013) Treatment of huntington disease. Curr Treat Options Neurol 15:424\u2013438","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"5428_CR98","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol Rev 90(3):905\u2013981","journal-title":"Physiol Rev"},{"issue":"6","key":"5428_CR99","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ncpneuro0199","volume":"2","author":"G Sadri-Vakili","year":"2006","unstructured":"Sadri-Vakili G, Cha J-HJ (2006) Mechanisms of disease: Histone modifications in Huntington\u2019s disease. Nature Clinical Practice Neurology 2(6):330\u2013338","journal-title":"Nature Clinical Practice Neurology"},{"issue":"5\u20136","key":"5428_CR100","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/17482960802566824","volume":"10","author":"A Chio","year":"2009","unstructured":"Chio A et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10(5\u20136):310\u2013323","journal-title":"Amyotroph Lateral Scler"},{"issue":"11","key":"5428_CR101","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1474-4422(07)70265-X","volume":"6","author":"J Phukan","year":"2007","unstructured":"Phukan J, Pender NP, Hardiman O (2007) Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 6(11):994\u20131003","journal-title":"Lancet Neurol"},{"issue":"1","key":"5428_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-020-01885-3","volume":"19","author":"SL Boddy","year":"2021","unstructured":"Boddy SL et al (2021) The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS). BMC Med 19(1):1\u201314","journal-title":"BMC Med"},{"issue":"16","key":"5428_CR103","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.3390\/ijms23169364","volume":"23","author":"B Roberts","year":"2022","unstructured":"Roberts B et al (2022) Synucleinopathy in amyotrophic lateral sclerosis: a potential avenue for antisense therapeutics? Int J Mol Sci 23(16):9364","journal-title":"Int J Mol Sci"},{"key":"5428_CR104","doi-asserted-by":"publisher","first-page":"1054006","DOI":"10.3389\/fphar.2022.1054006","volume":"13","author":"J Jiang","year":"2022","unstructured":"Jiang J, Wang Y, Deng M (2022) New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Front Pharmacol 13:1054006","journal-title":"Front Pharmacol"},{"issue":"7","key":"5428_CR105","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/00207454.2019.1702549","volume":"130","author":"AC Erber","year":"2020","unstructured":"Erber AC et al (2020) The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review. Int J Neurosci 130(7):727\u2013735","journal-title":"Int J Neurosci"},{"key":"5428_CR106","doi-asserted-by":"crossref","unstructured":"Prior-Gonz\u00e1lez, M., R. Lazo-G\u00f3mez, and R. Tapia, Sodium butyrate, a pan-histone deacetylase inhibitor, does not protect spinal motor neurons from AMPA-induced excitotoxic degeneration in vivo. Disease Models & Mechanisms, 2023: p. dmm. 049851.","DOI":"10.1242\/dmm.049851"},{"key":"5428_CR107","doi-asserted-by":"publisher","first-page":"686666","DOI":"10.3389\/fgene.2021.686666","volume":"12","author":"N Robinson","year":"2021","unstructured":"Robinson N, Bergen SE (2021) Environmental risk factors for schizophrenia and bipolar disorder and their relationship to genetic risk: current knowledge and future directions. Front Genet 12:686666","journal-title":"Front Genet"},{"key":"5428_CR108","unstructured":"Consortium, S.W.G.o.t.P.G. et al (2020) Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. MedRxiv p. 2020.09. 12.20192922."},{"key":"5428_CR109","doi-asserted-by":"crossref","unstructured":"Zhu F et al (2020) Role of short-chain fatty acids in the gut-brain axis in schizophrenia: contribution to immune activation and pathophysiology in humans and mice. BioRxiv p. 2020.04. 11.021915.","DOI":"10.1101\/2020.04.11.021915"},{"key":"5428_CR110","unstructured":"Lavretsky H (2008) History of schizophrenia as a psychiatric disorder. Clinical handbook of schizophrenia p. 3\u201313."},{"issue":"9","key":"5428_CR111","first-page":"638","volume":"39","author":"KR Patel","year":"2014","unstructured":"Patel KR et al (2014) Schizophrenia: overview and treatment options. Pharmacy and Therapeutics 39(9):638","journal-title":"Pharmacy and Therapeutics"},{"issue":"11","key":"5428_CR112","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/s41380-019-0475-4","volume":"25","author":"F Zhu","year":"2020","unstructured":"Zhu F et al (2020) Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice. Mol Psychiatry 25(11):2905\u20132918","journal-title":"Mol Psychiatry"},{"key":"5428_CR113","doi-asserted-by":"publisher","first-page":"724664","DOI":"10.3389\/fpsyt.2021.724664","volume":"12","author":"X Li","year":"2021","unstructured":"Li X et al (2021) The role of butyric acid in treatment response in drug-naive first episode schizophrenia. Front Psychiatry 12:724664","journal-title":"Front Psychiatry"},{"issue":"3","key":"5428_CR114","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.neuroimage.2012.04.005","volume":"61","author":"C Diener","year":"2012","unstructured":"Diener C et al (2012) A meta-analysis of neurofunctional imaging studies of emotion and cognition in major depression. Neuroimage 61(3):677\u2013685","journal-title":"Neuroimage"},{"key":"5428_CR115","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fpsyt.2018.00454","volume":"9","author":"J Li","year":"2018","unstructured":"Li J et al (2018) Short term intrarectal administration of sodium propionate induces antidepressant-like effects in rats exposed to chronic unpredictable mild stress. Front Psychiatry 9:454","journal-title":"Front Psychiatry"},{"key":"5428_CR116","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.brainres.2012.01.053","volume":"1447","author":"H Lin","year":"2012","unstructured":"Lin H et al (2012) Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex. Brain Res 1447:119\u2013125","journal-title":"Brain Res"},{"issue":"3","key":"5428_CR117","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s13311-011-0053-1","volume":"8","author":"B Ovbiagele","year":"2011","unstructured":"Ovbiagele B, Nguyen-Huynh MN (2011) Stroke epidemiology: advancing our understanding of disease mechanism and therapy. Neurotherapeutics 8(3):319\u2013329","journal-title":"Neurotherapeutics"},{"issue":"3","key":"5428_CR118","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/1673-5374.228711","volume":"13","author":"RH Lee","year":"2018","unstructured":"Lee RH et al (2018) Cerebral ischemia and neuroregeneration. Neural Regen Res 13(3):373","journal-title":"Neural Regen Res"},{"issue":"2","key":"5428_CR119","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1440-1681.2009.05279.x","volume":"37","author":"W Xia","year":"2010","unstructured":"Xia W et al (2010) Inflammation in ischaemic brain injury: current advances and future perspectives. Clin Exp Pharmacol Physiol 37(2):253\u2013258","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"5428_CR120","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/j.1471-4159.2009.06212.x","volume":"110","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Leeds P, Chuang DM (2009) The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem 110(4):1226\u20131240","journal-title":"J Neurochem"},{"issue":"2","key":"5428_CR121","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17482960802320487","volume":"10","author":"ME Cudkowicz","year":"2009","unstructured":"Cudkowicz ME et al (2009) Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 10(2):99\u2013106","journal-title":"Amyotroph Lateral Scler"},{"issue":"18_supplement","key":"5428_CR122","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1212\/WNL.98.18_supplement.131","volume":"98","author":"SE Arnold","year":"2022","unstructured":"Arnold SE et al (2022) Safety of a fixed-dose coformulation of sodium phenylbutyrate and taurursodiol in amyotrophic lateral sclerosis and Alzheimer\u2019s disease: integrated clinical trials experience (S11. 005). Neurology 98(18_supplement):131","journal-title":"Neurology"},{"issue":"3","key":"5428_CR123","doi-asserted-by":"publisher","first-page":"e12487","DOI":"10.1002\/trc2.12487","volume":"10","author":"SE Arnold","year":"2024","unstructured":"Arnold SE, Hendrix S, Nicodemus\u2010Johnson J, Knowlton N, Williams VJ, Burns JM, Crane M, McManus AJ, et al. (2024) Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions 10(3):e12487. https:\/\/doi.org\/10.1002\/trc2.12487","journal-title":"Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions"},{"issue":"10","key":"5428_CR124","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni S et al (2020) Trial of sodium phenylbutyrate\u2013taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 383(10):919\u2013930","journal-title":"N Engl J Med"},{"issue":"13","key":"5428_CR125","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/mds.21632","volume":"22","author":"P Hogarth","year":"2007","unstructured":"Hogarth P, Lovrecic L, Krainc D (2007) Sodium phenylbutyrate in Huntington\u2019s disease: a dose\u2010finding study. Mov Disord 22(13):1962\u20131964","journal-title":"Mov Disord"},{"key":"5428_CR126","doi-asserted-by":"publisher","first-page":"1522498","DOI":"10.3389\/fnagi.2025.1522498","volume":"17","author":"J Tu","year":"2025","unstructured":"Tu J, Zhang J, Chen G (2025) Higher dietary butyrate intake is associated with better cognitive function in older adults: evidence from a cross-sectional study. Front Aging Neurosci 17:1522498","journal-title":"Front Aging Neurosci"},{"key":"5428_CR127","doi-asserted-by":"publisher","first-page":"1304906","DOI":"10.3389\/fnins.2024.1304906","volume":"18","author":"S Yan","year":"2024","unstructured":"Yan S et al (2024) Protective effects of butyrate on cerebral ischaemic injury in animal models: a systematic review and meta-analysis. Front Neurosci 18:1304906","journal-title":"Front Neurosci"},{"issue":"16","key":"5428_CR128","doi-asserted-by":"publisher","first-page":"8998","DOI":"10.3390\/ijms25168998","volume":"25","author":"J Missiego-Beltr\u00e1n","year":"2024","unstructured":"Missiego-Beltr\u00e1n J et al (2024) Implications of butyrate signaling pathways on the motor symptomatology of Parkinson\u2019s disease and neuroprotective effects\u2014therapeutic approaches: a systematic review. Int J Mol Sci 25(16):8998","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5428_CR129","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3390\/ijms25063198","volume":"25","author":"L Barcutean","year":"2024","unstructured":"Barcutean L et al (2024) The immunomodulatory potential of short-chain fatty acids in multiple sclerosis. Int J Mol Sci 25(6):3198","journal-title":"Int J Mol Sci"},{"issue":"20","key":"5428_CR130","doi-asserted-by":"publisher","first-page":"9383","DOI":"10.3390\/app14209383","volume":"14","author":"L Pires","year":"2024","unstructured":"Pires L et al (2024) Gut microbiota as an endocrine organ: unveiling its role in human physiology and health. Appl Sci 14(20):9383","journal-title":"Appl Sci"},{"issue":"3","key":"5428_CR131","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0009-8981(89)90231-3","volume":"181","author":"P Daniel","year":"1989","unstructured":"Daniel P et al (1989) Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin Chim Acta 181(3):255\u2013263","journal-title":"Clin Chim Acta"},{"issue":"5","key":"5428_CR132","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41551-024-01190-x","volume":"8","author":"S Cao","year":"2024","unstructured":"Cao S et al (2024) A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice. Nat Biomed Eng 8(5):611\u2013627","journal-title":"Nat Biomed Eng"},{"key":"5428_CR133","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.mtbio.2025.101665","volume":"32","author":"J Zhao","year":"2025","unstructured":"Zhao J et al (2025) Nanoparticle-mediated sodium butyrate delivery for repairing hypoxic-ischemic brain injury in premature infants. Mater Today Bio 32:101665","journal-title":"Mater Today Bio"},{"issue":"9","key":"5428_CR134","doi-asserted-by":"publisher","first-page":"2402773","DOI":"10.1002\/adhm.202402773","volume":"14","author":"Y Lv","year":"2025","unstructured":"Lv Y et al (2025) Sodium butyrate\u2010loaded microspheres with enhanced bioavailability for targeted treatment of intestinal barrier injury. Adv Healthc Mater 14(9):2402773","journal-title":"Adv Healthc Mater"},{"key":"5428_CR135","doi-asserted-by":"publisher","first-page":"106434","DOI":"10.1016\/j.jff.2024.106434","volume":"121","author":"F Wan","year":"2024","unstructured":"Wan F et al (2024) Chemically protected sodium butyrate supplementation improves anti-inflammatory and antioxidant capacities potentially through modulating gut microbiota and short-chain fatty acids levels in piglets. J Funct Foods 121:106434","journal-title":"J Funct Foods"},{"key":"5428_CR136","doi-asserted-by":"publisher","first-page":"111385","DOI":"10.1016\/j.biopha.2021.111385","volume":"137","author":"R Russo","year":"2021","unstructured":"Russo R et al (2021) In vivo bioavailability and in vitro toxicological evaluation of the new butyric acid releaser N-(1-carbamoyl-2-phenyl-ethyl) butyramide. Biomed Pharmacother 137:111385","journal-title":"Biomed Pharmacother"},{"key":"5428_CR137","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1007\/s11064-020-03074-3","volume":"45","author":"C-M Qiao","year":"2020","unstructured":"Qiao C-M et al (2020) Sodium butyrate exacerbates Parkinson\u2019s disease by aggravating neuroinflammation and colonic inflammation in MPTP-induced mice model. Neurochem Res 45:2128\u20132142","journal-title":"Neurochem Res"},{"issue":"6","key":"5428_CR138","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson TR et al (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell 167(6):1469-1480. e12","journal-title":"Cell"},{"issue":"8","key":"5428_CR139","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/mds.29063","volume":"37","author":"X Yang","year":"2022","unstructured":"Yang X et al (2022) Parkinson\u2019s disease is associated with impaired gut\u2013blood barrier for short\u2010chain fatty acids. Mov Disord 37(8):1634\u20131643","journal-title":"Mov Disord"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05428-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T02:02:02Z","timestamp":1763604122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05428-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5428"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05428-w","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"90"}}